

# PRODUCT INFORMATION



## Vildagliptin carboxylic acid metabolite (trifluoroacetate salt)

Item No. 22088

CAS Registry No.: 565453-41-0

Formal Name: N-(3-hydroxytricyclo[3.3.1.1<sup>3,7</sup>]dec-1-yl)glycyl-L-proline, mono(trifluoroacetate)

MF: C<sub>17</sub>H<sub>26</sub>N<sub>2</sub>O<sub>4</sub> • CF<sub>3</sub>COOH


FW: 436.4

Purity: ≥95%

Supplied as: A solid

Storage: -20°C

Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

Vildagliptin carboxylic acid metabolite (trifluoroacetate salt) is supplied as a solid. A stock solution may be made by dissolving the vildagliptin carboxylic acid metabolite (trifluoroacetate salt) in the solvent of choice, which should be purged with an inert gas. Vildagliptin carboxylic acid metabolite (trifluoroacetate salt) is slightly soluble in methanol and DMSO.

Vildagliptin carboxylic acid metabolite (trifluoroacetate salt) is slightly soluble in aqueous solutions. To enhance aqueous solubility, dilute the organic solvent solution into aqueous buffers or isotonic saline. If performing biological experiments, ensure the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. We do not recommend storing the aqueous solution for more than one day.

### Description

Vildagliptin carboxylic acid metabolite is the major metabolite of the dipeptidyl peptidase 4 (DPP-4) inhibitor vildagliptin (Item No. 14705) in humans.<sup>1</sup> Vildagliptin carboxylic acid metabolite has an IC<sub>50</sub> value of 477 μM for DPP-4 in human Caco-2 cells.<sup>2</sup> It is formed from hydrolysis of the cyano group on vildagliptin.

### References

1. He, H., Tran, P., Yin, H., *et al.* Absorption, metabolism, and excretion of [<sup>14</sup>C]vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans. *Drug. Metab. Dispos.* **373**(3), 536-544 (2009).
2. Villhauer, E.B., Brinkman, J.A., Naderi, G.B., *et al.* 1-[[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: A potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. *J. Med. Chem.* **49**(13), 2774-2789 (2003).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/04/2022

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897  
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
WWW.CAYMANCHEM.COM